Patents by Inventor Puneet Tyagi

Puneet Tyagi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral delivery of GLP-1 peptide analogs
    Patent number: 11173124
    Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 16, 2021
    Assignee: MedImmune Limited
    Inventors: Sergei Pechenov, Puneet Tyagi, Janardhanan Anand Subramony
  • ORAL DELIVERY OF GLP-1 PEPTIDE ANALOGS
    Publication number: 20200323782
    Abstract: The present invention provides formulations for oral administration of GLP-1 peptide analogs, methods of making such formulations, and methods of treatment using such formulations.
    Type: Application
    Filed: October 30, 2018
    Publication date: October 15, 2020
    Inventors: Sergei PECHENOV, Puneet TYAGI, Janardhanan Anand SUBRAMONY
  • Transferrin-tumstatin fusion protein and methods for producing and using the same
    Patent number: 9290562
    Abstract: The present invention provides recombinant proteins comprising transferrin that is linked to tumstatin or other antiangiogenic protein and methods for producing and using the same. The present invention also provides an expression system, a plasmid, and a cell that is capable of expressing such recombinant proteins and methods for producing and using the same.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: March 22, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Uday B. Kompella, Robert I. Scheinman, Puneet Tyagi
  • Transferrin-Tumstatin Fusion Protein and Methods For Producing and Using the Same
    Publication number: 20140179612
    Abstract: The present invention provides recombinant proteins comprising transferrin that is linked to tumstatin or other antiangiogenic protein and methods for producing and using the same. The present invention also provides an expression system, a plasmid, and a cell that is capable of expressing such recombinant proteins and methods for producing and using the same.
    Type: Application
    Filed: August 15, 2012
    Publication date: June 26, 2014
    Applicant: The Regents of the University of Colorado, a body Corporate
    Inventors: Uday B. Kompella, Robert I. Scheinman, Puneet Tyagi
  • Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
    Patent number: 8664265
    Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: March 4, 2014
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Arno Appavoo Enose, Harish Kumar Madan, Sumit Madan, Anupam Trehan, Puneet Tyagi, Vinod Kumar Arora
  • STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS
    Publication number: 20120183607
    Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
    Type: Application
    Filed: July 14, 2011
    Publication date: July 19, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Arno Appavoo ENOSE, Harish Kumar MADAN, Sumit MADAN, Anupam TREHAN, Puneet TYAGI, Vinod Kumar ARORA
  • DENDRIMER HYDROGELS
    Publication number: 20110189291
    Abstract: Photoactivatable dendrimers and hydrogels formed therefrom include dendrimers to which polymer chains (e.g. polyethylene glycol, PEG) have been conjugated; and reactive photoactivatable groups attached to terminal functional groups of the polymer chains (e.g. hydroxyls of PEG). Exposure to a suitable wavelength of light activates the photoactivatable groups, which then crosslink with one another, thereby forming a hydrogel. The hydrogel may also include one or more agents of interest; or, in some embodiments, nanoparticles containing one or more agents of interest may be dispersed in the hydrogel. These formulations are well-suited for sustained or prolonged delivery of active agents, e.g. for the treatment of glaucoma by the sustained delivery of anti-glaucoma agents directly to the eye.
    Type: Application
    Filed: February 8, 2011
    Publication date: August 4, 2011
    Inventors: Hu Yang, Pooja N. Desai, Christopher A. Holden, Uday B. Kompella, Puneet Tyagi
  • STABLE DOSAGE FORMS OF SPIRO AND DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS
    Publication number: 20090042821
    Abstract: The field of the invention relates to stable dosage forms comprising spiro or dispiro 1,2,4-trioxolane antimalarials, or their pharmaceutically acceptable salts, prodrugs and analogues, and processes for their preparation. The water content of the dosage form is not more than 6.5% w/w.
    Type: Application
    Filed: May 18, 2006
    Publication date: February 12, 2009
    Inventors: Arno Appavoo Enose, Harish Kumar Madan, Sumit Madan, Anupam Trehan, Puneet Tyagi, Vinod Kumar Arora